Alzheimer's Drug Discovery Foundation

🌟 Exciting News 🌟 We are thrilled to announce a strategic investment from Labcorp Venture Fund and the Alzheimer's Drug Discovery Foundation (ADDF) in an #oversubscribed financing round led by DigitalDx Ventures, and joined by existing investors EIFO, and Hybsch Connect. These partnerships are a powerful testament to the groundbreaking science behind our #GLXSignaturePlatform and asset pipeline—a unique fusion of vascular biology and AI technology aimed at revolutionizing the care of people with neurological conditions. Our mission is to deliver transformative value for healthcare providers, pharma, and payors- and, above all, patients in need of more precise medicine. For more information, Press Release: https://lnkd.in/d_FjERTe #GLXAnalytix #Labcorp #ADDF #HealthcareInnovation #PersonalizedMedicine #Biomarkers #AI #DigitalDx #EIFO #HealthcareTransformation Brian DellaValle

"It's a big feast of #biomarkers." - Howard Fillit, MD speaks to the most promising science being presented at CTAD Clinical Trials on Alzheimer's Disease, beginning with new advances in #bloodtests that are revolutionizing the clinical care and research landscapes. Many of these promising blood tests are led by companies funded through the ADDF's #DiagnosticsAccelerator, including C2N Diagnostics, ALZpath Inc. and Fujirebio.

Progress around novel therapies informed by the biology of aging continues at CTAD Clinical Trials on Alzheimer's Disease. ADDF-funded Coya Therapeutics, Inc. reported positive results from their phase 2 trial of a novel drug that aims to enhance the function of regulatory T cells, which suppress #immune responses, showing the drug was safe and well-tolerated in #Alzheimers patients. This is one of many drugs in development that has the potential to be used in tandem with #antiamyloid therapies, moving us closer to treating Alzheimer's with a combination therapy approach. #CTAD24 https://bit.ly/3NKNIde via Reuters

Great to start off the #CTAD2024 week with the Alzheimer's Drug Discovery Foundation's (ADDF) symposium on advancements in novel therapeutics, combination therapies, and precision medicine. Miia Kivipelto moderated the morning session on Alzheimer's biomarkers and, later in the day, gave an update on the ADDF-supported MET-FINGER project, which explores the effects of combined #FINGER lifestyle interventions and the drug metformin on cognitive decline. Warm thanks to ADDF for your support and for arranging this important day full of edifying presentations and discussions. Thank you to all fellow researchers and partners. ✨ Joel Braunstein, MD Jeffrey Cummings Suzanne Schindler Charlotte Teunissen Henrik Zetterberg Howard Fillit, MD Mark Roithmayr #CTAD24 #alzheimer #dementia #dementiaprevention #precisionmedicine #combinationtherapies #METFINGER MET-FINGER: Metformin is provided as Glucophage®XR/SR 500mg oral tablets, together with matching placebo, by Merck Healthcare KGaA, Darmstadt, Germany

Joel Braunstein, MD, CEO of #C2N Diagnostics, presents at today’s ADDF Summit at CTAD on the Future of Alzheimer’s Biomarkers in Clinical Care and Research with other research luminaries Dr. Miia Kivipelto, Dr. Jeffrey Cummings, Dr. Suzanne Schindler, Dr. Charlotte Teunissen, Dr. Henrik Zetterberg, and Howard Fillit, MD. #Alzheimers #Alzheimersdisease #precisiomedicine #bloodtests #CTAD24 #ADDFSummit #biomarkers

Amazing panel of experts assembled by the ADDF to discuss blood and CSF biomarkers in dementia, present at future, and the virtuous cycle of discovering biomarkers and discovering medicines to treat diseases. Mark Roithmayr Howard Fillit, MD Joel Braunstein, MD Jeffrey Cummings Suzanne Schindler Miia Kivipelto Charlotte Teunissen Alzheimer's Drug Discovery Foundation

CTAD24 in Madrid being kicked off with ADDF’s Summit on Novel Therapuetics and Combination Therapy. First place to start—a Dream Team of Biomarker Panelists…

Looking forward to participating on this panel discussing neurodegenerative disease funding at #BioFuture2024

The ADDF's Chief Finance Officer and Head of Mission-Related Investing, Karen Bettauer Harris, will be speaking on a panel this morning at BIO Investor Forum. The session, titled, "Expansion of Neurodegenerative Disease Targets and Pipelines" is at 11 AM PT and will be moderated by Selina Koch, PhD. Panelists include Karen among industry leaders like Kasper Roet, Beth J Hoffman, David Bearss Ph.D., and Paul August. The panel will discuss advancements in #neurodegenerative disease #DrugDevelopment, the evolving landscape, #novel targets, and the implications for future #investment opportunities. See the full #BIF2024 program here: https://bit.ly/3NrhlA3